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Abstract  
Parents take an important role in follow-up of young cancer survivors. We aimed to investigate 1) parents’ 
preferences for organization of follow-up (including content, specialists involved and models of care), and 
2) parents’ and children’s characteristics predicting preference for generalist versus specialist-led follow-
up. We sent a questionnaire to parents of childhood cancer survivors aged 11-17years. We assessed on a 
four-point Likert scale (1-4), parents’ preferences for organization of long-term follow-up. Proposed 
models were: telephone/questionnaire, general practitioner (GP) (both categorized as generalist for 
regression analysis); and pediatric oncologist, medical oncologist or multidisciplinary team (MDT) 
(categorized as specialists). Of 284 contacted parents 189 responded (67%). Parents welcomed if visits 
included checking for cancer recurrence (mean=3.89), late effects screening (mean=3.79), taking patients 
seriously (mean=3.86, SD=0.35) and competent staff (mean=3.85). The preferred specialists were pediatric 
oncologists (mean=3.73). Parents valued the pediatric oncologist model of care (mean=3.49) and the MDT 
model (mean=3.14) highest. Parents of children not attending clinic-based follow-up (OR=2.97, p=0.009) 
and those visiting a generalist (OR=4.23, p=0.007) favored the generalist-led model. Many parents 
preferred a clinic-based model of follow-up by pediatric oncologists or a multidisciplinary team. However, 
parents also valued the follow-up care model according to which their child is followed up. 
Key words: parents of childhood cancer survivors; pediatric oncology; follow-up care; models of care; 
cancer registry, Europe 
 
INTRODUCTION 
Lifelong follow-up care is recommended for 
most childhood cancer survivors. The goal of 
follow-up is to identify and treat relapse and late 
effects early, and provide age-adapted 
information about cancer, treatment, potential 
late effects and health behavior. (Bhatia & 
Meadows, 2006; Hudson , et al., 2013; Oeffinger 
, et al., 2006; Taylor, Absolom, Snowden, Eiser, 
& Late Effects Group, 2012). Guidelines have 
been developed to provide recommendations for 
risk-stratified long-term follow-up care 
(Children's Oncology Group, 2008; Scottish 
Intercollegiate Guidelines Network (SIGN), 
2004; Wallace, Thompson, Anderson, & 
Guideline Development, 2013). Various models 
of care have been described and compared (Heirs 
, et al., 2013) such as follow-up by telephone 
(James, Guerrero, & Brada, 1994), 
multidisciplinary team (MDT) (Carlson, Hobbie, 
Brogna, & Ginsberg, 2008; Edgar & Wallace, 
2008), pediatric oncologist (Haddy & Haddy, 
2010), general practitioners (GP) (Schmidt , et 
al., 2010) or shared-care models (Blaauwbroek, 
Tuinier, Meyboom-de Jong, Kamps, & Postma, 
2008). In many countries, none of the models 
have been implemented and long-term follow-up 
is not standardized.  
In Switzerland, childhood cancers survivors are 
regularly followed-up by their pediatric 
oncologist into their early twenties, and are then 
usually discharged to a GP or medical oncologist. 
Others may continue follow-up with their 
pediatric oncologist longer into adulthood.  
Prior to setting up a specific model of follow-up 
care survivors’ and their parents’ opinions and 
preferences for the organization of care should be 
assessed (Aslett, Levitt, Richardson, & Gibson, 
2007; Earle, Davies, Greenfield, Ross, & Eiser, 
2005). Survivors’ opinions and preferences have 
previously been studied (Michel , et al., 2016; 
Michel , et al., 2009). Parents’ expectations of 
follow-up care have only been addressed in a 
small focus group study in the UK (Earle , et al., 
2005): parents desired medical facts and written 
test results for reassurance, information on 
psychosocial consequences, and wanted to have 
the possibility to meet other families with a child 
survivor. Parents did not value the GP model 
since they perceived that specialist knowledge 
was not available.  
Parents take an important role in follow-up care 
for many reasons: they are most aware about the 
child’s medical history but also provide things 
such as transportation or reminding about 
doctor’s appointment. We thus aimed to 
investigate 1) parents’ preferences for the 
organization of follow-up care (including 
content, specialists involved and different models 
of care). These outcomes were assessed for both 
children attending and not attending clinic-based 
follow-up. 2) We investigated associations of 
socio-demographic characteristics of parents and 
children’s clinical factors with preferences for 
generalist versus specialist-led follow-up.  
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METHODS 
Sample and procedure 
The Swiss Childhood Cancer Registry (SCCR) is 
a national population-based cancer registry 
including all cancer patients, diagnosed with 
leukemia, lymphoma, central nervous system 
(CNS) tumor, malignant solid tumor or 
Langerhans cell histiocytosis at age <21 years in 
Switzerland since 1976 (Michel , et al., 2007; 
Michel , et al., 2008). The Swiss Childhood 
Cancer Survivor Study (SCCSS) is a nationwide, 
long-term follow-up survey of the SCCR 
including a baseline (2007-2011) and a follow-up 
questionnaire (2010-2012). 
The baseline questionnaire included all patients 
registered in the SCCR who were diagnosed 
between 1976-2005, aged <21 years and survived 
for ≥5 years (Kuehni , et al., 2012a). Parents of 
survivors aged ≤15 years completed the 
questionnaire for their children, whereas 
survivors 16+ years completed their own 
questionnaire. 
The follow-up questionnaire was sent 
approximately 2 years later. Parents who filled in 
the baseline questionnaire were contacted again if 
their child who had cancer was aged 11-17 years 
at time of follow-up study (eligible N=306; 
Supplemental Figure 1). They received the 
questionnaire with a prepaid return envelope, and 
if they did not reply within two months, a 
reminder letter with another questionnaire. 
Questionnaires were available in German and 
French and focused on topics related to follow-up 
care.  
Ethics approval was provided through the 
general cancer registry permission of the SCCR 
(The Swiss Federal Commission of Experts for 
Professional Secrecy in Medical Research) and a 
non-obstat statement from the ethics committee 
of the canton of Bern declaring that the ethics 
committee did not object the conduct of the 
study.  
Measurements 
The follow-up survey of the SCCSS focused on 
follow-up care and psychological outcomes. 
Follow-up care after childhood cancer was 
introduced on the front page of the questionnaire 
as follow-up appointments of their child due to 
the previous severe disease. 
Outcome  
Items were purpose designed and based on a 
previous study in the UK (Michel , et al., 2009).  
What are the reasons for follow-up: Parents rated 
the importance (1=”not at all important” to 
4=”very important”; this scale was used in all 
questions where parents had to rate importance) 
of different reasons for attending follow-up (nine 
items).  
What should be included in follow-up: We asked 
parents about the perceived importance of four 
medical aspects and eight general aspects of 
follow-up (Figure 1A). 
What is important during appointments: Parents 
rated the importance of 10 organizational aspects 
(Figure 1A). 
Who should be involved in follow-up: Parents 
rated the importance of different medical and 
other specialists involved in follow-up (Figure 
1B). 
 
Models of care: We provided a short description 
of five different models of follow-up care by: a) 
telephone/questionnaire, (led by a nurse referring 
patients to specialist care if needed), b) GP-led 
and referring patients to a specialist if needed, c) 
pediatric oncologist who originally treated the 
survivor, d) medical oncologist, e) 
multidisciplinary team (MDT) in a hospital 
(defined as including several specialists such as 
oncologists, endocrinologists, psychologists, 
social workers and nurses, all of whom are 
accessible during one appointment). For each 
model we asked parents’ agreement to four items 
(1=“don’t agree at all” to 4=“completely agree”): 
‘it would suit my child’, ‘I am afraid that health 
problems are not detected’, ‘I am not satisfied 
with this kind of follow-up’, this model of 
follow-up is appropriate for the needs of their 
child.  
 
Explanatory variables assessed by questionnaire  
We assessed parents’ sex, age at study, migration 
background (migration if they were not Swiss 
citizens since birth or not born in Switzerland), 
language region (German vs. French), parents’ 
employment status (employed vs. not employed), 
and education (three categories: primary 
(compulsory schooling including vocational 
training/apprenticeship); secondary 
(teachers/technical and commercial schools etc.); 
tertiary (university and university of applied 
sciences; Table 1) (Kuehni , et al., 2012b). 
Additionally, we asked parents if their child still 
attended follow-up: 1) ‘yes, my child still attends 
regular follow-up appointments’; 2) ‘yes, my 
child still has irregular follow-up appointments’; 
3) ‘no, regular follow-up is completed, but my 
child goes to the doctor for any cancer-associated 
complications’; 4) ‘no, regular follow-up is 
completed and my child has not seen the doctor 
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for a while’. A binary variable was created: 
attenders (responses 1 or 2) and non-attenders 
(responses 3 or 4). Parents indicated on a list 
which doctors were involved in current care. This 
was coded as “specialist care” if parents listed at 
least one specialist and “generalist” if only a GP 
was indicated. Parents were asked whether they 
are currently involved in follow-up care (parental 
involvement=yes/no) (Vetsch , et al., 2016). 
Concerns of parents about consequences of their 
child's illness were assessed by the question 
“How concerned are you about consequences of 
your child's illness?” (adapted from the Brief 
Illness Perception Questionnaire (IPQ) using a 0-
to-10 response scale) (Broadbent, Petrie, Main, & 
Weinman, 2006). The response was divided in 
three categories (no: 0-2, medium: 3-6, and high 
concerns: 7-10).  
From the baseline questionnaire of the SCCSS 
we extracted information about parent-reported 
late effects of the survivor (yes/no) (Kuehni , et 
al., 2012a). 
 
Clinical variables of the child extracted from the 
SCCR  
We extracted medical information on cancer 
diagnosis and treatment of the child from the 
SCCR. Cancer diagnosis was classified according 
to the International Classification of Childhood 
Cancer (third edition) (Steliarova-Foucher, 
Stiller, Lacour, & Kaatsch, 2005). For the 
analyses we recoded diagnosis into six major 
groups: leukemia, lymphoma, CNS tumors, 
neuroblastoma, bone tumor/soft tissue sarcoma 
(STS) and other tumors. Treatment was coded as: 
surgery only, chemotherapy (without 
radiotherapy ±surgery), radiotherapy (±surgery 
and/or chemotherapy) and stem cell 
transplantation (SCT; may have had surgery 
and/or chemotherapy and/or radiotherapy). The 
type of treating hospital was divided into 
university and regional hospital. Age at diagnosis 
was divided into three categories: 0-1 year, 2-4 
years, ≥ 5 years. We have chosen these categories 
because they might influence risk for late effects 
and preferences for follow-up care. Age at study 
was divided into three categories: <14 years, 14-
15 years, >15 years. Time since diagnosis was 
divided into three categories 5-9 years, 10-14 
years and 15-17 years. Relapse was coded yes/no. 
Analyses 
Analyses were performed using Stata 13.1 
(StataCorp, College Station, TX).  
We used descriptive statistics to compare 
participants and non-participants of the study. For 
aim 1 we calculated means of the responses for 
each item. Paired t-tests were used to compare 
the means of clinical and supportive reasons. 
Hotelling t-test was used for the comparison of 
more than two means. Principal component 
analysis was used to test individual item loading 
onto different factors. The preference-score for 
each model of care was calculated as the overall 
mean of the four items assessed for each model. 
Two items had to be reverse coded such that 
higher scores indicated higher agreement (1-4). 
For each parent we determined the model with 
the highest preference-score. We then calculated 
the proportion of parents indicating each 
respective model as their preferred one (Figure 2) 
and stratified it by the model their child is 
currently attending (Figure 3). Parents could have 
more than one model reaching the highest 
preference-score.  
To analyze difference in preferences between 
attenders and non-attenders we used t-test and 
chi2-test. Bonferroni correction was used to 
correct for multiple testing.  
For aim 2 we determined the model with the 
highest mean for each parent and created a binary 
variable indicating if GP or 
telephone/questionnaire follow-up (generalist 
follow-up=1) or any other follow-up model was 
rated highest (pediatric, medical oncologist, 
MDT: specialist follow-up=0, Table 2). 
Telephone/questionnaire and GP led model were 
grouped into generalist model because survivors 
would first contact a health care provider not 
necessarily specialized in pediatric oncology and 
only be referred to a specialist if needed. We 
used univariable logistic regression to investigate 
associations of parents’ and their child’s 
characteristics with the preferences for generalist 
versus specialist follow-up.  
RESULTS 
Of 306 eligible parents, we traced and contacted 
284 (Supplemental Figure 2). Of those 
contacted, 189 (67%) responded. The mean age 
of parents was 46.1 years (SD=4.8, range 33.5-
59.5 years), mean age of the child at study was 
14.8 years (SD=1.8, range 10.7-18.0 years), mean 
age at diagnosis was 3.4 years (SD 2.5 range 0-
9.2 years) and the mean time since diagnosis 11.3 
years (SD 2.5, range 6.8-17.2 years; Table 1). 
Most children were diagnosed with leukemia 
(39.2%) followed by CNS tumors (18.0%). 
Participating and non-participating parents were 
similar in socio-demographic and clinical 
characteristics (Table 1).  
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1) Parents’ preferences for organization of 
follow-up care  
What are the reasons for follow-up: Factor 
analysis revealed two scales: supportive care (get 
reassurance about health, talk to staff who 
understand my child has been through, get advice 
about how to stay healthy, receive psychological 
support, get advice about everyday things) and 
clinical care (get information about late effects, 
check the cancer has not come back, help clinic 
staff learn more about late effects, get the best 
medical care). Cronbach’s alpha, a measure for 
internal consistency, was good for supportive 
care: α=0.73; but low for clinical care α=0.58. 
Parents valued clinical reasons (mean=3.75, 
SD=0.33) higher than supportive reasons 
(mean=3.11, SD=0.58; p<0.001).  
What should be included in follow-up: Among 
clinical aspects, parents rated check for cancer 
recurrence as most important (mean=3.91, 
SD=0.36; Figure 1A), before screen for late 
effects (mean=3.79, SD=0.45; p<0.001) and 
information on potential late effects (mean=3.65, 
SD=0.57; p<0.001). Regarding general aspects, 
knowing about risks for their child’s offspring 
was rated as most important (mean=3.12, 
SD=0.82) whereas exchange with other former 
patients (mean=2.29, SD=0.91) and 
religion/spirituality were rated least important 
(mean=1.68, SD=0.79). 
What is important during appointments: Parents 
rated patient is taken seriously (mean=3.86, 
SD=0.35; Figure 1A) and competent staff 
(mean=3.85, SD=0.37) as most important 
aspects, and significantly more important than the 
quality of relationship to medical staff 
(mean=3.75, SD=0.52; p=0.002). Least important 
were short consultation (mean=2.55, SD=0.81) 
and meet former patients (mean=2.16, SD=0.82). 
Who should be involved in follow-up: When we 
asked about staff who should be involved in 
follow-up care parents rated the pediatric 
oncologist as most important (mean=3.73, 
SD=0.68) and significantly more important than 
general practitioners (mean=3.28, SD=0.89; 
p<0.001; Figure 1B). Radiotherapist 
(mean=2.02, SD=0.95) and social workers 
(mean=1.95, SD=0.90) were least important. 
Models of follow-up care: For each model, we 
calculated the overall mean score among all 
parents. Additionally, we calculated the number 
of parents who had the highest preference-score 
for the respective model compared to all other 
models (Figure 2). Most parents preferred 
follow-up by a pediatric oncologist (N=117, 
61.9%, mean=3.49, SD=0.65), followed by MDT 
(N=72, 38.1%, mean=3.16, SD=0.74; p<0.001), 
GP (N=55, 29.1%, mean=2.71, SD=0.97) and 
medical oncologist (N=54; 28.6%, mean=2.84, 
SD=0.86). Only few parents preferred the 
telephone/questionnaire model (N=9, 4.8%, 
mean=1.81, SD=0.79). The pediatric oncologist 
and MDT model were rated significantly higher 
than the other three models (all p<0.001). When 
stratified for the model their child is currently 
attending, parents whose child attended specialist 
follow-up preferred the pediatric oncologist 
model (44.6%) followed by MDT (21.6%). 
Parents whose child saw a generalist preferred 
the GP model (29.1%) but also had preferences 
for specialist-led follow-up care (Figure 3).  
There was no difference in preferences for 
follow-up between parents of attenders and non-
attenders after Bonferroni correction 
(Supplemental Table 1).  
2) Associations with parents’ preferences for 
generalist versus specialist-led follow-up: 
We used logistic regression analyses to determine 
characteristics of parents and clinical 
characteristics of the child associated with 
preferences for generalists follow-up (GP and 
telephone/questionnaire) versus specialist follow-
up (pediatric or medical oncologist, MDT; Table 
2). Parents of children not attending follow-up 
care (OR=2.97, CI 1.33-6.60, p=0.009) or already 
visiting a generalist for follow-up (OR=4.23, CI 
1.84-9.71, p=0.007) rated the generalist model 
higher. A trend could be seen for lower 
preferences for generalist follow-up care for 
parents of children who had had a relapse 
(OR=0.23, CI 0.03-1.78, p=0.083) and who had 
been treated in a regional hospital (OR=0.31, CI 
0.07-1.39, p=0.080).  
 
DISCUSSION 
We found that clinical reasons to attend follow-
up were more important than supportive reasons 
to parents of childhood cancer survivors aged 11-
17 years. Medical aspects such as checking for 
cancer recurrence or screening for late effects 
were rated as most important. Parents wanted that 
their child is taken seriously and competent staff 
is available. Pediatric oncologists and GPs were 
rated as the preferred doctors. Parents’ preferred 
model of care was pediatric oncologist-led 
follow-up or follow-up by a MDT. The generalist 
model was only favored by parents of children 
not attending follow-up care at a treating clinic or 
who already see a generalist.  
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The importance of medical aspects during 
follow-up was already reported in previous 
studies (Christen , et al., 2016; Earle , et al., 
2005; Eiser, Levitt, Leiper, Havermans, & 
Donovan, 1996; Michel , et al., 2016; Michel , et 
al., 2009). We reported that screening for late 
effects and check for cancer recurrence was rated 
most important for parents which are in line with 
what survivors reported. Parents want to be 
reassured about the cancer and know that their 
child is in best current health. A focus group 
analysis of parents of survivors aged 13-25 years 
showed that it is important to learn about risks for 
future health but also about how to stay healthy 
(Earle , et al., 2005). This is in contrast to our 
results where the general aspects such as risk for 
offspring were rated less important. The 
survivors in our samples are young and future 
health might not be of biggest concern, however 
parents and survivors should be informed that 
many years after diagnosis the risk for cancer 
recurrence diminishes and follow-up care is of 
higher importance to screen for late effects and 
learn about healthy lifestyle (Reulen , et al.). 
 
When we asked for the specialist which should 
be involved parents preferred the pediatric 
oncologist followed by the GP. This preference 
for the pediatric oncologist was in line with 
another Swiss study on childhood cancer 
survivors (Michel , et al., 2016). In contrast to 
our findings a previous focus group reported that 
follow-up at a GP was evaluated as not 
appropriate since the specialist knowledge was 
lacking, whereas clinics led by specialist nurses 
were perceived as more acceptable, in offering 
both specialist expertise and opportunities for 
appropriate feedback (Earle , et al., 2005). 
However, these survivors were still in clinic-
based follow-up most likely by a pediatric 
oncologist and therefore possibly favoring this 
specialist. Even though second highest in our 
study, another study in the US on survivors 
showed that follow-up by primary care 
physicians was rated highest and the late effects 
specialist second highest only (Zebrack , et al., 
2004). Concerning might be that other studies 
reported that generalists lack knowledge and 
information on potential late effects or comfort of 
care for childhood cancer survivors (Lawrence, 
McLoone, Wakefield, & Cohn, 2016; Mertens , 
et al., 2004). Therefore, a close collaboration 
with specialist should be guaranteed and 
educational interventions for GPs if required 
organized. A Dutch study showed that GP are 
willing to follow-up childhood cancer survivors 
in a shared-care model, however they saw lack of 
information and communication as a barrier 
(Blaauwbroek , et al., 2007). Therefore written 
treatment summaries or a passport for care should 
be provided and help the GP guide through 
recommended screening and follow-up care 
processes (Horowitz, Fordis, Krause, McKellar, 
& Poplack, 2009). Such a passport will be 
implemented across Switzerland within the next 
years. 
 
We additionally showed that most parents 
preferred follow-up care by a pediatric oncologist 
or a MDT led model. The 
telephone/questionnaire led model was least 
preferred. This is in line with two other studies 
among survivors who reported the pediatric 
oncologist-led follow-up as most important and 
the telephone/questionnaire follow-up least 
important (Michel , et al., 2016; Michel , et al., 
2009). However, in the UK they only included 
survivors who attended clinic-based follow-up 
which was most likely led by a pediatric 
oncologist. Also expert committees have often 
favored long-term follow-up care clinics led by a 
MDT because late effects might be diverse and 
complex (Wallace , et al., 2001). With the ever 
growing population of survivors, follow-up care 
by pediatric oncologists however will not be 
feasible and manageable in Switzerland and 
MDT models might be too cost intensive. 
Therefore, in Switzerland many survivors are 
transitioned to a GP. Our results also indicated 
that parents of Swiss survivors still seeing a 
pediatric oncologist favor the pediatric 
oncologist-led follow-up, and parents whose 
children see a GP favor the generalist model. 
These parents also know specialist care from the 
first 5-10 years follow-up by the pediatric 
oncologist. Our results thus suggest that a risk-
stratified approach where low-risk survivors are 
transferred to GP-led follow-up could meet 
parents’ preferences. These findings are 
supported by another Swiss study where we 
showed that adolescent and young adult survivors 
preferred follow-up by medical oncologists, most 
of whom were treated by medical oncologists 
(Christen , et al., 2016). As shown in another 
study on adult survivors satisfaction with care did 
not depend on the clinic type but rather on shorter 
waiting time and possibilities to discuss health 
concerns (Absolom , et al., 2006). Parents and 
survivors preferences and satisfaction of care 
should be taken into account as it might ensure 
future attendance in follow-up. 
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We found no other clinical or socio-demographic 
associations for preferences for generalist-led 
follow-up care. Neither diagnosis nor late effects 
were associated with different preferences for 
follow-up care. However, there was some 
indication for a generalist preference in parents of 
survivors who did not have a relapse and those 
treated at a university hospital. This might 
suggest that preferences do not reflect the risk for 
late effects.  
 
Our results and previous findings suggest that 
survivors and parents might be happy and feel 
comfortable with the model of care their children 
are currently receiving. Preference of care might 
be related to the satisfaction of care even though 
not measured in our study. Parents’ preferences 
of care should therefore be considered early on 
and, if possible, follow-up care should be framed 
taking their preferences into account. Being the 
primary caregiver of young survivors their 
preference and satisfaction of care might ensure 
later attendance at follow-up care. However, 
parents should also be given adequate assurance 
and support in taking the decision on the future 
health care provider. Alternative models and 
individual preferences of long-term follow-up 
should be discussed. Additionally, both health 
care providers and primary caregivers might 
profit from written treatment summaries and 
survivorship care plans and guarantee adequate 
follow-up. A risk-stratified approach, where 
survivors receive follow-up care depending on 
diagnosis, and treatment (indicating their risk for 
late effects) might be the most adequate approach 
(Eiser , et al., 2006). However, for Switzerland 
such an approach has so far not been 
implemented (Rebholz , et al., 2011).  
 
A limitation of this study is self-selection: parents 
of specific groups such as parents with greater 
interest in follow-up care or with higher needs 
may have been more willing to complete the 
questionnaire, others have been excluded because 
they did not complete the baseline questionnaire. 
Additionally, we only contacted one parent, 
mostly mothers, and thus information on 
preferences of the other parent is lacking. Also, 
we did not contact the survivors themselves in 
these families, and thus the preference of care of 
survivors is lacking. Another limitation is that we 
cannot tell if this is what parents really prefer or 
what they have been told to do by the treating 
physician. Further, we were not able to stratify 
survivors according to their risk because detailed 
information on exact treatment was lacking. The 
small sample size resulted in reduced precision 
and large confidence intervals. Therefore, only 
limited stratification of results was possible. 
Other limitations are the low reliability of the 
scale “clinical reasons” and the self-reported late 
effects. 
Despite the relatively small sample size, this is a 
study with a rather large sample of parents of 
childhood cancer survivors compared to previous 
research. We were able to include parents of 
survivors attending and not attending clinic-based 
follow-up, and included prospectively collected 
data from the SCCR and from two questionnaires 
from the SCCSS. The response rate was good 
(67%).  
 
Follow-up is an important aspect of quality of 
survivorship. In the transitioning phase from 
child to adult care it is important to not only meet 
survivors’ or providers’ preferences, but also 
parents’ preferences for the organization of 
follow-up care. This might avoid a future loss to 
follow-up. We showed that many parents prefer a 
clinic-based model of follow-up by pediatric 
oncologists or a multidisciplinary team. 
However, parents also valued the follow-up care 
model according to which their child is followed 
up. 
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Table 1. Characteristics of the study population, comparing parents participating and not 
participating in the questionnaire survey 
  
 Participating parents Non-participating parents 
  N % N % 
Total 189 100 117 100 
Socio-demographic characteristics of parents  
Sex     
  Female 160 84.7 n.a.d 
n.a. 
 
  Male 29 15.3  
Age at study     
  ≤45 years 93 49.2 n.a.  
  >45 years 96 50.8 n.a.  
Migration background    
  Swiss 173 91.5 n.a.  
  Migration background 16 8.5 n.a.  
Language region     
  German 132 70.2 78 66.7 
  French  56 29.8 39 33.3 
Education      
  Primary  101 54.3 n.a.  
  Secondary 62 33.3 n.a.  
  Tertiary 23 12.4 n.a.  
Employment      
  Employed 150 79.4 n.a.  
  Unemployed 39 20.6 n.a.  
Clinical characteristics of the child    
Diagnosis     
  Leukemias 74 39.2 46 39.3 
  Lymphomas 16 8.5 10 8.5 
  CNS tumors 34 18.0 23 19.7 
  Neuroblastoma 13 6.9 8 6.8 
  Retinoblastoma 13 6.9 5 4.3 
  Renal tumors 12 6.3 8 6.8 
  Hepatic tumors 4 2.1 3 2.6 
  Malignant tumors 2 1.1 3 2.6 
  Soft tissue sarcomas 14 7.4 3 2.6 
  Germ cell tumors 2 1.1 3 2.6 
  LCH 2 1.1 3 2.6 
  Othera 3 1.6 0 0.0 
Treatment receivedb     
  Surgery only 30 16.0 20 17.5 
  Chemotherapy 118 63.1 74 64.9 
  Radiotherapy 30 16.0 17 14.9 
  SCT 9 4.9 3 2.6 
Type of treating hospital    
  University hospital 160 84.7 102 87.2 
  Regional hospital 29 15.3 15 12.8 
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Table 1 contd. 
 
 
Note: Percentages are based upon available data for each variable. Abbreviations: CNS, Central Nervous System; 
LCH, Langerhans Cell Histiocytosis; n.a., not available; N, Number; SCT, Stem Cell Transplantation; SD, Standard 
Deviation; aOther: malignant epithelial neoplasms, malignant melanomas and other or unspecified malignant 
neoplasms; bChemotherapy may include surgery, radiotherapy may include chemotherapy and/or surgery. 
 
 Participating parents Non-participating parents 
 N % N % 
Total 189 100 117 100 
Child’s age at diagnosis     
0-1 years 58 30.7 35 29.9 
2-4 years 82 43.4 48 41.0 
5+ years 49 25.9 34 29.1 
Time since diagnosis     
  5-9 years 64 33.9 38 32.5 
  10-14 years 96 50.8 58 49.6 
  15-17 years 29 15.3 21 17.9 
Child’s age at study     
  <14 years 60 31.8 36 30.8 
  14-15 years 43 22.7 17 14.5 
  >15 years 86 45.5 64 54.7 
Relapse      
  No  168 88.9 104 88.9 
  Yes 21 11.1 13 11.1 
Parent-reported late effects    
  No  100 54.4 68 64.2 
  Yes 84 45.6 38 35.8 
Parental involvement in follow-up    
  No 10 7.1 n.a.  
  Yes 130 92.9 n.a.  
Follow-up attendance     
Yes 141 74.6 n.a.  
No 48 25.4 n.a.  
 Participants Non-participantsa 
 Mean SD Mean SD 
Parent’s age 46.1 4.8 n.a. n.a. 
Child’s age at study 14.7 1.8 15.0 1.9 
Child’s age at diagnosis 3.4 2.2 3.6 2.4 
Time since diagnosis 11.3 2.5 11.4 2.5 
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Table 2. Factors associated with preferences for follow-up care by generalists 
(GP/Telephone-led follow-up) versus specialists (from univariable logistic regression models) 
  
 
 Preference for 
generalist follow-up Univariable regression  
 N Total N % OR 95%CI p 
Socio-demographic characteristics of parents  
Sex      0.300 
 Female 158 29 18.4 1   
 Male 28 3 10.73 0.53 0.15-1.89  
Age at study       0.894 
 ≤45 years 91 16 17.6 1   
 >45 years 95 16 16.8 0.95 0.44-2.03  
Migration background     0.176 
 Swiss 170 31 18.2 1   
 Immigrant 16 1 6.3 0.30 0.04-2.35  
Language region      0.127 
 German 131 19 14.5 1   
 French 54 13 24.1 1.86 0.85-4.12  
Education      0.379 
 Primary 100 20 20.0 1   
 Secondary 60 7 11.7 0.53 0.21-1.34  
 Tertiary 23 4 17.4 0.84 0.26-2.75  
Employment      0.490 
 Employed 148 24 16.2 1   
 Unemployed 38 8 21.1 1.38 0.56-3.37  
Clinical characteristics of the child    
Diagnosis      0.657 
 Leukemia 72 16 22.2 1   
 Lymphoma 16 3 18.7 0.81 0.20-3.19  
 CNS tumor 34 6 17.7 0.75 0.26-2.13  
 Neuroblastoma 12 2 16.7 0.70 0.14-3.53  
 Bone tumor/STS 16 1 6.3 0.23 0.03-1.90  
 Other tumora 24 3 12.5 0.5 0.13-1.89  
Treatment receivedb      0.297 
 Surgery 29 7 24.1 1   
 Chemotherapy 117 19 16.2 0.61 0.23-1.63  
 Radiotherapy 29 2 6.9 0.23 0.04-1.24  
 SCT 9 2 22.2 0.90 0.15-5.36  
Type of treating hospital     0.080 
 University hospital 157 30 19.1 1   
 Regional hospital 29 2 6.9 0.31 0.07-1.39  
Child’s age at diagnosis     0.214 
 0-1 years 56 6 10.7 1   
 2-4 years 82 18 21.9 2.34 0.87-6.34  
 5+ years 48 8 16.7 1.67 0.53-5.20  
Child’s age at study     0.381 
 <14 years 60 8 13.3 1   
 14-15 years 42 6 14.3 1.08 0.35-3.39  
 >15 years 84 18 21.4 1.77 0.71-4.40  
Time since diagnosis     0.556 
 5-9 years 64 11 17.2 1   
 10-14 years 94 18 19.2 1.14 0.50-2.62  
 15-17 years 28 3 10.7 0.58 0.15-0.40  
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Table 2 contd. 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Numbers for each outcome vary because not all participants answered each question. Percentages are based 
upon available data for each variable. Abbreviations: CI, Confidence Interval; CNS, Central Nervous System; GP, 
General practitioner; OR, Odds Ratio; N, Number; p, p-value; SCT, Stem Cell Transplantation; aOther: malignant 
epithelial neoplasms, malignant melanomas and other or unspecified malignant neoplasms; bChemotherapy may 
include surgery, radiotherapy may include chemotherapy and/or surgery;  
  
 N Total N % OR 95%CI p 
Relapse      0.083 
 No 166 31 18.7 1   
 Yes 20 1 5.0 0.23 0.03-1.78  
Parent-reported late effects     0.521 
 No 99 18 18.2 1   
 Yes 82 12 14.6 0.77 0.35-1.72  
Parental involvement in follow-up    0.766 
 No 10 1 10.0 1   
 Yes 129 17 13.2 1.36 0.16-11.47  
Concerns about consequences of cancer   0.289 
 No 50 12 24.0 1   
 Medium 54 7 13.0 0.47 0.17-1.31  
 High 80 12 15.0 0.56 0.23-1.37  
Follow-up attendance      0.009 
 Yes 140 18 12.3 1   
 No 46 14 20.0 2.97 1.33-6.60  
Doctors involved in current care    0.007 
 Specialist  123 13 10.6 1   
 Generalist 29 16 33.3 4.23 1.84-9.71  
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Figure 1. Parents’ preferences for the organization of follow-up care 
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Figure 2. Parents’ preferred model of follow-up care 
 
 
Figure 2 shows on the left side the proportion (bars) of parents rating the respective model as their most 
preferred follow-up care model (highest mean score among all the models; parents could have more than one 
preferred model reaching the same highest score), and on the right side the four point likert scale and the 
mean values (square symbols) 
Abbreviations: N=number 
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Figure 3. Parents’ preferred follow-up care model stratified by the model their child is 
currently attending (Specialist vs generalist) 
 
 
Figure 3 shows the proportion of parents rating the respective model as their preferred follow-up care model 
stratified by the model their child is currently attending (highest mean score among all the models; parents 
could have more model which they preferred most)  
 
 
